Investigator

Christos V. Chalitsios

University of Oxford, Nuffield Department of Clinical Neurosciences

CVCChristos V. Chali…
Papers(3)
Positivity Rate of PD…Unravelling the assoc…The role of sleep tra…
Collaborators(9)
Georgios MarkozannesEmmanouela-Aliki Almp…Emmanouil BourasKonstantinos DinasKonstantinos FlindrisStamatios PetousisStefanos FlindrisChrysoula Margioula-S…Aristarchos Almperis
Institutions(4)
University Of IoanninaAristotle University …Imperial College Lond…General Hospital Of I…

Papers

Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis

The prevalence and prognostic value of programmed death ligand 1 (PD-L1) expression, as a potential biomarker in vulvar squamous cell carcinomas (VSCCs), remain underexplored. We searched the PubMed, Scopus, Embase, and Cochrane Library databases until July 2024 for articles examining PD-L1 expression in VSCCs. Random-effects meta-analyses summarized PD-L1 expression overall and in subgroups by immunohistochemistry antibody type, positivity cutoff, tumor stage, and HPV positivity. Additionally, random-effects meta-analyses summarized the association between PD-L1 positivity and cancer prognosis. We included 26 studies comprising 1912 VSCC cases. The summary PD-L1 positivity rate in tumor cells was 59.9% (95% confidence interval [CI]: 47.7–71.4%; I2 = 96%, n = 26), influenced by the different cutoff thresholds utilized to define PD-L1 positivity. Compared to tumor cells, positivity rates were higher in intratumoral immune cells (75.6%; 95%CI: 52.9–92.5; I2 = 95.4%, n = 6) and peritumoral cells (78.9%; 95%CI: 54.4–95.5%; I2 = 91%, n = 3) but with overlapping 95%CIs. No heterogeneity was observed in the rates by tumor stage or HPV status. Positive PD-L1 expression was associated with worse overall (hazard ratio [HR] = 1.43; 95%CI: 1.06–1.93; I2 = 28.9%, n = 7) and progression-free survival (HR = 1.57; 95%CI: 1.07–2.3; I2 = 38.3%, n = 5). The PD-L1 expression rate in VSCC tumor cells varied across studies, was influenced by differences in immunohistochemical evaluation, and was identified as an unfavorable prognostic factor. Large, prospective, multicenter studies with standardized protocols are crucial to further elucidate the clinical significance of PD-L1 expression in VSCCs.

37Works
3Papers
9Collaborators

Positions

Researcher

University of Oxford · Nuffield Department of Clinical Neurosciences

2020–

Research assistant

University of Nottingham · School of Medicine, Division of Epidemiology and Public Health

Education

2021

Ph.D in Respiratory Epidemiology

University of Nottingham · School of Medicine, Division of Respiratory Medicine

2017

M.Sc in Epidemiology and Biostatistics

University of Thessaly · Scool of Medicine

2015

B.Sc (hons) in Mathematics

University of Ioannina · Faculty of Science

Country

GB

Keywords
Big dataepidemiologybiostatistics
Links & IDs
0000-0002-0836-9385Linkedin

Scopus: 57214867084